Combination therapies for the treatment of cancer
US-2017182003-A1 · Jun 29, 2017 · US
Combination therapies for the treatment of cancer
US11707448B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11707448-B2 |
| Application number | US-202117528510-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 17, 2021 |
| Priority date | May 23, 2014 |
| Publication date | Jul 25, 2023 |
| Grant date | Jul 25, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.
First claim
Opening claim text (preview).
We claim: 1. A method of treating a subject having colorectal cancer or melanoma or pancreatic cancer, comprising administering to the subject, an EP4 antagonist in combination with an antibody therapy, wherein the EP4 antagonist is: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein said treating comprises an abscopal effect. 3. The method of claim 1 , wherein the antibody therapy is CTLA4 antibody therapy. 4. The method of claim 1 , wherein the subject has colorectal cancer. 5. The method of claim 1 , wherein the cancer is metastatic cancer. 6. A method of generating a memory immune response in a subject having colorectal cancer or melanoma or pancreatic cancer, comprising administering to the subject, an EP4 antagonist in combination with an antibody therapy, and wherein the EP4 antagonist is: or a pharmaceutically acceptable salt thereof. 7. The method of claim 6 , wherein said generating the memory immune response comprises an abscopal effect. 8. The method of claim 6 , wherein the antibody therapy is CTLA4 antibody therapy. 9. The method of claim 6 , wherein the subject has colorectal cancer. 10. The method of any of claim 6 , wherein the cancer is metastatic cancer. 11. The method of claim 6 , wherein the memory immune response comprises epitope spreading. 12. The method of claim 1 , wherein the method further comprises administering an anti-metabolite chemotherapy in combination with the EP4 antagonist and antibody therapy. 13. A method of treating a subject having colorectal cancer or melanoma or pancreatic cancer, comprising administering to the subject, an EP4 antagonist in combination with an anti-metabolite chemotherapy, wherein the EP4 antagonist is: or a pharmaceutically acceptable salt thereof. 14. The method of claim 6 , wherein the memory immune response further comprises administering an anti-metabolite chemotherapy in combination with the EP4 antagonist and antibody therapy. 15. The method of claim 1 , wherein the antibody therapy is PDL1 antibody therapy. 16. The method of claim 1 , wherein the antibody therapy is PD1 antibody therapy. 17. The method of claim 6 , wherein the antibody therapy is PDL1 antibody therapy. 18. The method of claim 6 , wherein the antibody therapy is PD1 antibody therapy. 19. The method of claim 1 , wherein the subject has melanoma. 20. The method of claim 1 , wherein the subject has pancreatic cancer. 21. The method of claim 6 , wherein the subject has melanoma. 22. The method of claim 6 , wherein the subject has pancreatic cancer.
Assignees
Inventors
Classifications
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
comprising antibodies · CPC title
Preparations for use in therapy · CPC title
against B7 molecules, e.g. CD80, CD86 · CPC title
against CD28 or CD152 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11707448B2 cover?
- The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.
- Who is the assignee on this patent?
- Eisai R&D Man Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/415. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).